Cargando…

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals

We have investigated the evolution of the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants at 8 months after Pfizer-BNT162b2 vaccination in coronavirus disease 2019 (COVID-19)–naive (n = 21) and COVID-19–convalescent (n = 21) individuals. Neutralizi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luczkowiak, Joanna, Labiod, Nuria, Rivas, Gonzalo, Rolo, Marta, Lasala, Fátima, Lora-Tamayo, Jaime, Mancheno-Losa, Mikel, Rial-Crestelo, David, Pérez-Rivilla, Alfredo, Folgueira, María Dolores, Delgado, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755312/ https://www.ncbi.nlm.nih.gov/pubmed/34963008 http://dx.doi.org/10.1093/infdis/jiab634

Ejemplares similares

Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
por: Luczkowiak, Joanna, et al.
Publicado: (2021)

Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19
por: Folgueira, Maria Dolores, et al.
Publicado: (2021)

The role of DC-SIGN as a trans-receptor in infection by MERS-CoV
por: Labiod, Nuria, et al.
Publicado: (2023)

Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak
por: McEllistrem, M. Catherine, et al.
Publicado: (2021)

Immune Senescence Markers Predict the Cellular Immune Response to BNT162b2 Vaccination in Hemodialysis Patients
por: Van Praet, Jens T, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
por: Luczkowiak, Joanna, et al.
Publicado: (2022)

Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients
por: Fu, Jia, et al.
Publicado: (2022)

Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers
por: Coggins, Si’Ana A, et al.
Publicado: (2021)

BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
por: Zacay, Galia, et al.
Publicado: (2021)

Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease
por: Luczkowiak, Joanna, et al.
Publicado: (2018)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
por: Tani, Naoki, et al.
Publicado: (2022)

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
por: Atıcı, Serkan, et al.
Publicado: (2023)

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
por: Ionescu, Iulia G, et al.
Publicado: (2023)

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
por: Leung, Nancy H L, et al.
Publicado: (2022)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center
por: Tau, Luba, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Genotypic and Phenotypic Characteristics of Staphylococcus aureus Prosthetic Joint Infections: Insight on the Pathogenesis and Prognosis of a Multicenter Prospective Cohort
por: Muñoz-Gallego, Irene, et al.
Publicado: (2020)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
por: Speich, Benjamin, et al.
Publicado: (2022)

Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study
por: Tau, Luba, et al.
Publicado: (2023)

Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma
por: Bonny, Tania S, et al.
Publicado: (2020)

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
por: Hurme, Antti, et al.
Publicado: (2022)

Quantification and Progress Over Time of Specific Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in Breast Milk of Lactating Women Vaccinated With BNT162b2 Pfizer-BioNTech Coronavirus Disease 2019 Vaccine (LacCOVID)
por: Esteve-Palau, Erika, et al.
Publicado: (2022)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 Pseudomonas aeruginosa Isolates
por: Recio, Raúl, et al.
Publicado: (2022)

Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome
por: Villalaín, Cecilia, et al.
Publicado: (2020)

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2022)

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
por: Thépaut, Michel, et al.
Publicado: (2021)

TLR7 Activation in M-CSF-Dependent Monocyte-Derived Human Macrophages Potentiates Inflammatory Responses and Prompts Neutrophil Recruitment
por: Simón-Fuentes, Miriam, et al.
Publicado: (2023)

Immune Response Kinetics Following a Third Heterologous BNT162b2 Booster Dose After Primary 2-Dose ChAdOx1 Vaccination in Relation to Omicron Breakthrough Infection: A Prospective Nationwide Cohort Study in South Korea
por: Ahn, Jin Young, et al.
Publicado: (2023)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine
por: Wong, Matthew K., et al.
Publicado: (2022)

Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses
por: Lasala, Fátima, et al.
Publicado: (2021)

Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents
por: Canaday, David H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uas9984f48o6u9og484f8j073b